Gedeon Richter PLC (0QFP) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Gedeon Richter PLC stock £74.50, price £50.40, upside +47.8%, quality 81 out of 100. Rating: undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Gedeon Richter PLC
0QFP · LSECheap (32% below fair value) and strong company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 19, 2026.
How to read this chart
60‑month range £50.18 – £119.31 · fair‑value band £55.87 – £93.12 · the £50.40 price screens below the £74.50 fair value. As of Oct 19, 2026.
Company profile
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products.
Show moreShow less
It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives.
It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases.
In addition, it produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic.
Further, it engages in the provision of financial accounting, social and welfare, portfolio management, catering, carriage transportation, engineering, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment.
It has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management.
Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, "FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
Stock analysis
Gedeon Richter PLC (0QFP) currently trades at £50.40, while our model-based Fair Value estimate is £74.50, implying the stock looks roughly 32% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of £122.85 per share, and 18 of the 25 models we run sit above the £50.40 price.
Bear case: the Asset-Based group reads lowest at £14.71, and 7 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: £55.87 (bear) to £93.12 (bull), the price of £50.40 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Gedeon Richter PLC reported revenue of £567B in FY2020 versus £390B in FY2016, a compound +9.8%/yr. Reported net income was £105B in FY2020, compounding +12.1%/yr from FY2016.
Key figures
Market cap £1.5T · P/S ratio 1.61 · Net margin 23.3% · Return on equity 16.2% · Return on assets (EBIT) 6.3% (5-year average) · Operating margin 33.0% · Revenue (TTM) £925B · EPS growth (quarter YoY) −26.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 58% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at 48%, 0QFP screens cheaper than that median.
Fair Value models
All 25 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch 0QFP, get fair value alerts →
Compare Gedeon Richter PLC with another stock
Price, fair value, quality and upside side by side.
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $79.11 | $113.53 | +44% | vs 0QFP |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.00 | ¥51.70 | +10% | vs 0QFP |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,884.90 | ₹1,982.92 | +5% | vs 0QFP |
| Haleon plc HLN | $9.07 | $8.47 | −7% | vs 0QFP |
| Merck KGaA MRK | €146.45 | €108.83 | −26% | vs 0QFP |
| Galderma Group GALD | CHF 182.85 | CHF 112.84 | −38% | vs 0QFP |
| Teva Pharmaceutical Industries Limited TEVA | $39.23 | $20.74 | −47% | vs 0QFP |
| Takeda Pharmaceutical Company TAK | $21.77 | $11.26 | −48% | vs 0QFP |
| Sandoz Group SDZ | CHF 80.50 | CHF 40.87 | −49% | vs 0QFP |
| Divi's Laboratories Limited DIVISLAB | ₹11,180.50 | ₹1,566.89 | −86% | vs 0QFP |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Gedeon Richter PLC (0QFP) overvalued or undervalued?
What is the fair value of 0QFP?
What is the quality score of 0QFP?
What is the price target for Gedeon Richter PLC (0QFP)?
What is the Gedeon Richter PLC stock forecast for 2026?
What is the revenue of Gedeon Richter PLC (0QFP)?
What is the intrinsic value of Gedeon Richter PLC (0QFP)?
Is Gedeon Richter PLC stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 0QFP?
How much is Gedeon Richter PLC worth?
What do the bullish and bearish scenarios say about 0QFP?
How far is 0QFP from its 52-week high?
Which stocks are comparable to Gedeon Richter PLC?
Is Gedeon Richter PLC stock attractive at the current price?
How is the fair value of 0QFP calculated?
Is it still worth investing in stocks now?
What is the share price of Gedeon Richter PLC (0QFP)?
What should I pay attention to with Gedeon Richter PLC right now?
Key figures of Gedeon Richter PLC
How large is the market capitalisation of Gedeon Richter PLC (0QFP)?
What is the P/S ratio of Gedeon Richter PLC (0QFP)?
What is the net margin of Gedeon Richter PLC (0QFP)?
What is the return on equity of Gedeon Richter PLC (0QFP)?
What is the EBIT return on assets of Gedeon Richter PLC (0QFP)?
What is the operating margin of Gedeon Richter PLC (0QFP)?
How fast are earnings growing at Gedeon Richter PLC (0QFP)?
Continue in the live analysis
Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.